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Background: Noninvasive biomarkers to guide personalized treatment for
castration-resistant prostate cancer (CRPC) are needed. In this study, we analyzed
hypermethylation patterns of two genes (GSTP1 and APC) in plasma cell-free DNA
(cfDNA) of CRPC patients. The aim of this study was to analyze the cfDNA
concentrations and levels of the epigenetic markers and to assess the value of
these biomarkers for prognosis.
Methods: In this prospective study, patients were included before starting new
treatment after developing CRPC. The blood samples were collected prior to start of
the treatment and at three time points thereafter. cfDNAwas extracted from1.5mL of
plasma and before performing a methylation-specific PCR, bisulfate modification was
carried out.
Results: The median levels of cfDNA, GSTP1, and APC copies in the baseline samples
of CRPC patients (n = 47) were higher than in controls (n = 30). In the survival analysis,
the group with baseline marker levels below median had significant less PCa-related
deaths (P-values <0.02) and did not reach the median survival point. The survival
distributions for the groups were statistically significant for the cfDNA concentration,
GSTP1 and APC copies, as well as PSA combined with GSTP1 + APC (P-values <0.03).
Furthermore, there were strong positive correlations between PSA and marker
response after starting treatment (P-values <0.04).
Conclusions: In conclusion, this study showed the kinetics of methylated cfDNA
(GSTP1andAPC) in plasmaofCRPCpatients after starting treatment. Furthermore, the
value of the markers before treatment is prognostic for overall survival. These results
are promising for developing a test to guide treatment-decision-making for CRPC
patients.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2018 The Authors. The Prostate Published by Wiley Periodicals, Inc.
Abbreviations: ACTB, β-actin; ADT, androgen deprivation therapy; APC, adenomatous polyposis coli; AR, androgen receptor; AR-V7, androgen receptor splice variant 7; CRPC, castration
resistant prostate cancer; cfDNA, cell-free DNA; CTC, circulating tumor cells; GSTP1, gluthathione-S-tranfsferase π; IQR, interquartile range; PCa, prostate cancer; PSA, prostate-specific
antigen; RASSF1A, ras association domain family protein 1 isoform A; RECIST, response evaluation criteria in solid tumors.
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1 | INTRODUCTION
Most patients with advanced prostate cancer (PCa) will eventually
develop castration-resistant prostate cancer (CRPC). CRPC was
accounting for over 26 000 deaths in the US in 2016.1 Significant
improvements have been made in the treatment options for CRPC.
Approved treatments are chemotherapy (docetaxel, cabazitaxel),
androgen receptor (AR)-targeted agents (enzalutamide and abirater-
one acetate), and radiopharmaceuticals (Radium-223).2–8 However,
there are currently no biomarkers to guide personalized treatment
decisions. Monitoring of treatment response is mostly done 3-4
months after starting treatment, with measuring PSA levels and bone
scintigraphy and/or other imaging modalities.9
Blood-based biomarkers are promising to provide more molec-
ular information on metastatic PCa than the primary tumor or a
single metastasis alone.10 In the blood of advanced PCa patients
circulating tumor cells (CTC) derived from the primary tumor and
metastatic sites11 can be detected, as well as cell-free, cancer-
derived nucleic acids like DNA and RNA.10 Circulating cell-free DNA
(cfDNA) is composed of small fragments of nucleic acids that are
not associated with cells or cell fragments.12 Jung et al. showed
that cfDNA levels were higher in metastatic PCa patients and were
predictive for PCa-specific survival.13 The detection of PCa-specific
genetic and epigenetic alterations within the cfDNA potentially is
more useful.14,15
The most common epigenetic alteration in PCa is DNA CpG island
hypermethylation and previous studies showed detection of hyper-
methylated DNA in blood of PCa patients.16 GSTP1 hypermethylation
was detected in 12% of patients with clinically localized PCa and 28%
of patient with hormone refractory metastatic PCa.17 Furthermore,
GSTP1 hypermethylation was shown to be the strongest predictor of
PSA recurrence following radical prostatectomy17 and was correlated
with the Gleason score and the extent of metastasis in patients with
hormone-refractory PCa.18 GSTP1 has been studied in combination
with other hypermethylated genes, such as APC and RASSF1A. A
recent meta-analysis showed that a higher level of hypermethylated
APC is associated with biochemical recurrence of patients with
prostate cancer.19 The combination of these genes is used in a
diagnostic tissue-based test for PCa.20
We analyzed the hypermethylation patterns of CRPC patients in
plasma cfDNA of two genes (GSTP1 and APC) and the housekeeping
gene ACTB. The aim of this study was (i) to analyze the cfDNA
concentrations and levels of methylated markers (GSTP1 and APC) in
plasma of CRPC patients; (ii) to assess the value of the methylated
markers as prognostic factor for overall survival; and (iii) to evaluate
the association between the cfDNA and methylated markers changes
in response to treatment.
2 | MATERIALS AND METHODS
2.1 | Patient population
In this prospective study, patients were enrolled prior to the start
of chemotherapy (docetaxel or cabazitaxel) or androgen receptor
signaling inhibitors (abiraterone, enzalutamide) after developing
CRPC on androgen deprivation therapy (ADT). This was the primary
treatment after developing CRPC. The subjects were included
between February 2013 and March 2016, and treated at the Radboud
university medical center (Nijmegen, The Netherlands). Exclusion
criteriawere a history of othermalignancies in the last 5 years, baseline
PSA level ≤5.0 ng/mL (to reduce the chance of non-informative
samples) and radiation therapy within 30 days of entry. Clinical data
was extracted from the patients records. Approval was obtained from
the Institutional Review Board and written informed consent was
obtained from each patient. The control groups consisted of ten
healthy age-matched men with no evidence of PCa, ten men aged
under 35 years of age and 10 healthy women.
2.2 | Blood samples and cfDNA extraction
The blood samples were collected prior to the start of treatment and at
week 15, week 27, and week 42. The blood collection was part of a
scheduled follow-up appointment, not focusing on the status of the
disease. The blood samples were collected into an EDTA tube of 9mL.
The EDTA tubes were centrifuged at 1.300g for 10min after which
plasmawasextractedandstoredwithin twohours at−80°C. cfDNAwas
extracted from1.5mLofplasmausing theQuick-cfDNASerum&Plasma
kit (Zymo Research D4076). First, a centrifugation step of 16.000g for
10min was performed to ensure efficient depletion of residual cells,
cell debris, and genomic DNA.21 Supernatant was then transferred to a
new 2.0mL Eppendorf tube and extraction was performed following
manufacturers protocol. The cfDNA was eluted in 27 μl of elution
buffer. Size and yield of cfDNAwas evaluated on a high sensitivityDNA
chip of the Agilent 2100 Expert Bioanalyzer (Agilent Technologies Inc.
Santa Clara, CA) and with the dsDNA High Sensitivity assay kit on a
Qubit 3.0 fluorimeter (Thermo Fisher Scientific, Eugene, OR).
2.3 | Bisulfite treatment
A total of 20 μl of cfDNA was used for the bisulphite modification
using a commercially available kit (EZ DNA Methylation-Lightning Kit,
Zymo D5030, Zymo Research, Orange, CA). This reaction selectively
deaminates unmethylated cytosine residues, resulting in a conversion
to uracil, while 5-methyl cytosine residues are not modified. The
modified cfDNA was eluted into 25 μl EL-Buffer (1 mM Tris-HCl,
pH8.0), then stored at −80°C before further processing.
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2.4 | Methylation-specific PCR
A multiplex Taqman probe-based approach was used to detect
methylated copies of GSTP1 and APC (Table S1 in Appendix A
−Supplementary data). ACTB was used as a housekeeping gene.20 A
custom plasmid vector containing the relevant fragments of each of
the three genes (IDT, Iowa) was included as a standard curve.
Amplification of the multiplex methylation-specific PCR assay was
performed on the Lightcycler LC480 (Roche Ltd., Basel, Switzerland)
with PerfeCTa multiplex qPCR ToughMix (Quantabio, Beverly, MA)
in a total volume of 20 µL containing 1x buffer, 0.2 µmol/L of each
primer and 0.2 μmol/L of each probe. As a positive control we used
in vitro methylated DNA (Milipore). As a negative control we used
DNA extracted from HCT116 cell line with knocked out methyl-
transferases. Methylation-specific PCR conditions were: 95°C for
3min to activate the Hotstart enzyme followed by 45 cycles of
95°C for 15 sec and 60°C for 1min. Detection was performed with
following filter combinations: FAM (465-510), CFO 560 (533-580),
CFR 610 (533-610), and Q670 (618-660). Results were generated
using the Lightcycler 480 software's (Roche) Abs quant/2nd
derivate max and exported as Ct values (cycler number at which the
amplification curves crossed the automatically set threshold value).
These Ct values were used to calculate copy numbers based on a linear
regression of the triplicate points of the standard curve of 8E + 06-8
plasmid copies. A run was considered valid when R2 of at least five
relevant data points of the standard curve was above 0.99; PCR
efficiency was >80% and the no template control was negative. For
the sample data, results were considered valid when the Ct of ACTB
was detected within the standard curve (>80 copies).
2.5 | Statistical analysis
The study must be considered of exploratory nature and hypothesis-
generating. Hypermethylated GSTP1 and APC copies were combined
as one factor with the principal component analysis, as well as the
combination of themethylatedmarkers with PSA. Differences in levels
of cfDNA and methylated markers between controls and CRPC
patients were analyzed using the Mann–Whitney U test. For survival
analysis Kaplan–Meier curves and the log rank test was used. To
evaluate the correlation between PSA response and marker responses
after starting treatment Spearman's correlation coefficient (rs) was
determined. Significance levels of P < 0.05were concluded statistically
significant. Statistical tests were performed using SPSS version 22.0
(IBM Corp., Armonk, NY).
3 | RESULTS
3.1 | Study population
In this prospective study 50 CRPC patients were included. Three
subjects were excluded because one patient had been included twice
and two patients had no biomarker levels in the baseline blood
samples. Furthermore, 10 age-matched man (median age 64 years
[interquartile range IQR 58-67]), 10 men younger than 35 years old
(median age 27 years [IQR 26-29]), and 10 women (median age
55 years [IQR 35-66]) were sampled as controls. The patient
characteristics are summarized in Table 1. The median age of patients
was 68 years (IQR 60-71 years) and median baseline PSA was
108 ng/mL.
3.2 | Detection of cfDNA and hypermethylation
markers in plasma of CRPC patients
The median levels of cfDNA in the baseline samples of the CRPC
patients were significantly higher than in the age-matched controls
and men <35 years (P < 0.01 and P < 0.01, respectively) (Table 2
and Figure 1). The median level of cfDNA in the female controls
was lower than in the CRPC patients, although not statistically
significant (P = 0.07). Hypermethylation of GSTP1 and APC could
not be measured in all samples probably because the copy numbers
TABLE 1 Patient characteristics
n = 47 (IQR/%)
Age (median, yrs) 68 (60-71)
Metastasize status, n
Primary M+ diagnosis 30 (64%)
M+ after primary treatment 13 (28%)
Unknown 4 (8%)
Primary treatment, n
Radical prostatectomy 13 (28%)
External radiation therapy 14 (30%)
Brachytherapy 1 (2%)
Prior systemic treatment, n
Androgen deprivation 47 (100%)
Chemotherapy 8 (17%)
Treatment at inclusion, n
Docetaxel 22 (47%)
Cabazitaxal 2 (4%)
Abiraterone 16 (34%)
Enzalutamide 7 (15%)
Samples available for analysis, n
Baseline 47 (100%)
2nd timepoint 47 (100%)
3rd timepoint 37 (79%)
4th timepoint 25 (53%)
sPSA, ng/mL (median)
Baseline PSA 108 (35.0-220)
2nd timepoint 38.1 (3.6-140.0)
3rd timepoint 34.0 (3.5-76.2)
4th timepoint 19.0 (2.9-155.0)
Follow-up, months (median) 18 (11-26)
Patients died of PCa, n 18 (38%)
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were below the detection limit (Table 2). Hypermethylation of
GSTP1 was observed in 91% of CRPC patients at baseline with a
median of 32 copies. This was significantly higher than in the 5
(71%) age-matched controls (median 2 copies; P < 0.01) and in 6
(86%) men <35 years (median 14 copies; P = 0.02). There was no
statistical difference with the 9 (100%) women (median 14 copies;
P = 0.13). APC was statistically significant lower in all control
groups (age-matched men P < 0.01, men <35 years P < 0.01, and
women P < 0.01) compared to the CRPC patients (median of 59
copies) (Table 2).
3.3 | Prognostic value of baseline cfDNA and
epigenetic markers
At the time of analysis 18 (38%) of the patients had died from PCa.
The median follow-up was 18 months (IQR 11-26 months). To
assess the prognostic value of the baseline levels of cfDNA and
methylated markers, survival analysis was performed. The patients
were divided into two groups: a group with the baseline level
below the median and a group with a baseline level higher than
the median. Figure 2 shows the Kaplan–Meier analysis of overall
TABLE 2 cfDNA and biomarker levels in PCa patients versus controls
PCa patients
Age-matched
men
Men aged
<35 yrs Women
Time point 1 2 3 4 - - -
No. patients 47 47 37 25 10 10 10
Exclusion‡ 0 2 (4%) 2 (4%) 0 3 (30%) 3 (30%) 1 (10%)
Yield bioanalyzer
(median [IQR])
5.0 (3.4-9.6) 6.9 (3.7-10.2) 6.9 (4.0-12.7) 5.7 (3.6-8.7) 2.6 (2.0-4.0)
P < 0.01*
1.9 (1.4-2.6)
P < 0.01*
2.7 (2.4-7.4)
P = 0.07
cfDNA ng/mL
bioanalyzer
3.4 (2.2-6.4) 4.6 (2.4-6.8) 4.6 (2.6-8.5) 3.8 (2.4-5.8) 1.7 (1.3-2.7)
P < 0.01*
1.2 (0.9-1.7)
P < 0.01*
1.8 (1.6-4.9)
P = 0.07
ACTB (evaluable
samples)
Copies (median
[IQR])
47 (100%)
330 (2-764)
45 (100%)
258 (2-669)
35 (100%)
27 (2-764)
25 (100%)
219 (2-725)
7 (100%)
286 (232-531)
P = 0.20
7 (100%)
239 (200-274)
P = 0.09
9 (100%)
489 (306-1407)
P = 0.15
GSTP1 (evaluable
samples)
Copies (median
[IQR])
43 (91%)
32 (7-83)
38 (84%)
11 (2-46)
25 (71%)
16 (10-147)
22 (88%)
68 (7-167)
5 (71%)
2 (2-16)
P < 0.01*
6 (86%)
14 (2-87)
P = 0.02*
9 (100%)
14 (2-37)
P = 0.13
APC (evaluable
samples)
Copies (median
[IQR])
37 (79%)
59 (14-138)
25 (56%)
31 (12-172)
26 (74%)
26 (5-88)
24 (96%)
50 (13-183)
3 (43%)
12 (10-12)
P < 0.01*
1 (14%)
10
P <0.01*
4 (44%)
15 (7-23)
P < 0.01*
‡Exclusion samples with ACTB calculated copies below the detection limit (<80 copies ACTB).
*Statistically significant different from patient baseline samples (Mann–Whitney U test, significance level P < 0.05).
FIGURE 1 cfDNA concentrations and methylated GSTP1 and APC copies in patients versus controls
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survival in association with the cfDNA concentration, level of the
methylated markers and the combined factors GSTP1+APC and
PSA+GSTP1+APC. For all markers, the group with baseline levels
below median did not reach the median survival point. Patients
with a cfDNA concentration below the median of 3.4 ng/mL had
a significant lower number of deaths than the patients with a
baseline value >3.4 ng/mL (21% vs 57%, P = 0.02) and a better
overall survival (log rank P = 0.01). There was also a significant
difference in overall survival for methylated GSTP1 baseline level
below median compared to a higher GSTP1 Level (P = 0.02) and for
FIGURE 2 Kaplan–Meier analysis of overall survival according to baseline values of cfDNA (A) and methylated markers (B-D) and the
combination of PSA with GSTP1+APC (E)
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methylated APC baseline levels (P = 0.03). When using the
combined factor GSTP1+APC, there were significant less deaths
in the group with the baseline value below the median (21% vs
57%, P = 0.02). Furthermore, survival analysis showed a trend
to better overall survival in the low level group, although not
statistically significant (P = 0.07). De combination of PSA with
GSTP1 and APC resulted in a significant better overall survival
for patients with a baseline value below median (P = 0.01).
3.4 | cfDNA and methylated markers response after
treatment as survival predictors
To evaluate the association with overall survival, patients were
stratified into four groups with the median of the baseline sample used
as cutoff-point: (i) both samples below baseline median; (ii) first sample
below baseline median and second sample higher; (iii) both samples
higher than baseline median; and (iv) first sample higher and second
sample below baseline median. There were statistically significant less
PCa-related deaths in the group with cfDNA and markers below
median at baseline and the first timepoint (P-values <0.02). A Log rank
test was run to determine if there were differences in the survival
distributions for the four patient groups. The patient group with both
samples below baselinemedian had significantly higher overall survival
for all markers (Figure S1, Appendix A−Supplementary data).
4 | DISCUSSION
To guide personalized treatment decisions in advanced PCa, reliable
markers are needed to monitor disease activity and as predictors for
survival. In this study, we found higher concentrations of cfDNA and
higher levels of methylated markers in blood plasma of CRPC patients
compared to healthy controls. Furthermore, the baseline levels of
cfDNA and GSTP1/APC before starting treatment were prognostic
for overall survival.
In this study, blood plasma was used to extract cfDNA. Serum
contains higher cfDNA concentrations, however, serum is known to be
contaminated by genomic DNA.21 Several studies have demonstrated
that the increased level of cfDNA in serum is mainly due to lysis of the
clotting white blood cells in the collection tubes. Thijssen et al22
showed that plasma DNA better reflects the in vivo concentrations of
cfDNA than serum DNA. The measured level of cfDNA has been
shown to be greatly influenced by blood-sampling, processing and
cfDNA-extraction protocols.23 The Bioanalyzer used in this study
specifically measures cfDNA instead of genomic DNA.
Previous studies showed that PCR-based methods are able to
detect minimal amounts of nucleic acids,24 on the other hand, the
necessary bisulfate treatment for the used methylation-specific PCR
could result in degradation of DNA and therefore limited detection
of very few copies of methylated DNA.17 In our study, 71-91% of
samples at the different timepoints had detectable levels of
methylated GSTP1. For methylated APC, this was 56-90% of the
samples. This in is accordance with previous studies, in which a
detection rate of 79-95% of PCa cases for GSTP1 hypermethylation
was reported and 27-100% for APC hypermethylation.25
There were strong, positive correlations between PSA and marker
responses after starting treatment (rs 0.305-0.636), which were all
statistically significant (P < 0.04). We evaluated the 11 cases in which
the PSA level increased after starting treatment, to determine the
prognostic value of the methylated markers in this group. There was a
statistical difference in the survival distribution for the groups based
on median baseline levels for GSTP1 copies (P = 0.004) and the
combination of GSTP1+APC (P = 0.004).
Our results show that the cfDNAyield in samples asmarker itself is
a prognostic factor for overall survival. It would be very interesting to
compare cfDNA level with CTC count. Especially because, De Bono
et al11 showed that the number of CTC in peripheral blood has strong
independent prognostic value in patients with metastatic CRPC when
measured before start of treatment. Moreover, whenmeasured during
therapy an increase in CTC count was associated with reduced overall
survival, especially shortly after introducing a new treatment.26
However, for CTC analysis the time frame between blood sampling,
sample preparation and analysis needs to be as small as possible and it
is more complicated than the methylation-specific PCR. If cfDNA yield
is equal or even better in predicting prognosis of CRPC patients, even
stored blood plasma samples could be used for analysis. This could
improve feasibility of using these markers in daily practice.
The limitations of this study: most importantly, the heterogeneity
of the study population with patients receiving chemotherapy versus
abiraterone acetate or enzalutamide. In addition, the number of PCa-
related deaths was relatively small and, therefore, the median overall
survival difference could not be studied. Furthermore, there was little
information available about the controls. In our analysis, several
controls had detectable levels of GSTP1 methylation in the cfDNA
(Table 2), however, in a previous study, no hypermethylation of GSTP1
was observed in healthy controls.16 However, also in PCa patients the
detection rate of hypermethylation of GSTP1 was lower in this study
with 42.3% versus 91% in our study.16
Despite its explorative character, this study indicates that pre-
treatment levels of cfDNA and epigenetic markers (GSTP1 and APC)
are of prognostic value for CRPC patients. Moreover, measuring the
variation of levels after starting treatment could potentially improve
monitoring treatment response. Standardization and uniform stand-
ards for collection, processing and analysis are needed to study these
markers. Besides, studies with matched control and patient groups are
essential. Future research should include monitoring of disease
progression with imaging and the radiological RECIST criteria.27
Moreover, it would be very interesting to collect samples at more
timepoints short after starting treatment.
5 | CONCLUSIONS
In conclusion, this study evaluated cfDNA concentrations in plasma
cfDNA of CRPC patients and the levels of methylated GSTP1 and APC.
The baseline value of the markers before starting treatment was
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prognostic for overall survival. Furthermore, the variation of levels
after starting treatment are promising to improve personalized
treatment of CRPC patients in the future.
CONFLICTS OF INTEREST
The authors would like to declare the following conflicts of interest:
Smit, VanderSmissen, and Van Voorde are employees of MDxHealth.
Mulders, Van Criekinge, and Schalken report consultancy with
honoraria for MDxHealth. The other authors declare no potential
conflicts of interest.
ACKNOWLEDGMENTS
This research was funded by MDxHealth (Irvine, CA).
ORCID
Inge M. van Oort http://orcid.org/0000-0002-8002-1869
Jack A. Schalken http://orcid.org/0000-0001-8274-7797
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin.
2016;66:7–30.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone
or mitoxantrone plus prednisone for advanced prostate cancer.N Engl
J Med. 2004;351:1502–1512.
3. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel
or mitoxantrone for metastatic castration-resistant prostate cancer
progressing after docetaxel treatment: a randomised open-label trial.
Lancet. 2010;376:1147–1154.
4. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment
ofmetastatic castration-resistant prostate cancer: final overall survival
analysis of the COU-AA-301 randomised, double-blind, placebo-
controlled phase 3 study. Lancet Oncol. 2012;13: 983–992.
5. Ryan CJ, SmithMR, Fizazi K, et al. Abiraterone acetate plus prednisone
versus placebo plus prednisone in chemotherapy-naive men with
metastatic castration-resistant prostate cancer (COU-AA-302): final
overall survival analysis of a randomised, double-blind, placebo-
controlled phase 3 study. Lancet Oncol. 2015;16:152–160.
6. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide
in prostate cancer after chemotherapy. N Engl J Med. 2012;367:
1187–1197.
7. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic
prostate cancer before chemotherapy.NEngl JMed. 2014;371:424–433.
8. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and
survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
9. Onstenk W, de Klaver W, de Wit R, Lolkema M, Foekens J, Sleijfer S.
The use of circulating tumor cells in guiding treatment decisions for
patients with metastatic castration-resistant prostate cancer. Cancer
Treat Rev. 2016;46:42–50.
10. Hegemann M, Stenzl A, Bedke J, Chi KN, Black PC, Todenhofer T.
Liquid biopsy: ready to guide therapy in advanced prostate cancer?
BJU Int. 2016;19.
11. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor
cells predict survival benefit from treatment in metastatic
castration-resistant prostate cancer. Clin Cancer Res. 2008;14:
6302–6309.
12. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the
possible origin and mechanism of circulating DNA apoptosis and
active DNA release. Clin Chim Acta. 2001;313:139–142.
13. Jung K, Stephan C, Lewandowski M, et al. Increased cell-free DNA in
plasma of patients with metastatic spread in prostate cancer. Cancer
Lett. 2004;205:173–180.
14. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity
in cancer patients. Cancer Res. 2003;63:3966–3968.
15. Ellinger J, Muller SC, Stadler TC, Jung A, von Ruecker A, Bastian PJ.
The role of cell-free circulating DNA in the diagnosis and prognosis of
prostate cancer. Urol Oncol. 2011;29:124–129.
16. Ellinger J, Haan K, Heukamp LC, et al. CpG island hypermethylation in
cell-free serumDNA identifies patients with localized prostate cancer.
Prostate. 2008;68:42–49.
17. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1
CpG island hypermethylation and the risk of early prostate-specific
antigen recurrence following radical prostatectomy. Clin Cancer Res.
2005;11:4037–4043.
18. Reibenwein J, Pils D, Horak P, et al. Promoter hypermethylation of
GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and
its clinical relevance. Prostate. 2007;67:427–432.
19. Wang Y, Fan C, Yu J, Wang X. APC methylation predicts biochemical
recurrence of patients with prostate cancer: a meta-analysis. Int J Clin
Exp Med. 2015;8:15575–15580.
20. Van Neste L, Bigley J, Toll A, et al. A tissue biopsy-based epigenetic
multiplex PCR assay for prostate cancer detection. BMC Urol.
2012;12:16.
21. ElMessaoudi S,Rolet F,Mouliere F, ThierryAR.Circulating cell freeDNA:
Preanalytical considerations. Clin Chim Acta. 2013;23:222–230.
22. Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between
free circulating plasma and serumDNA in patients with colorectal liver
metastases. Anticancer Res. 2002;22:421–425.
23. Chiu RW, Poon LL, Lau TK, Leung TN, Wong EM, Lo YM. Effects of
blood-processing protocols on fetal and total DNA quantification in
maternal plasma. Clin Chem. 2001;47:1607–1613.
24. Bastian PJ, Palapattu GS, Yegnasubramanian S, et al. Prognostic value
of preoperative serum cell-free circulating DNA in men with prostate
cancer undergoing radical prostatectomy. Clin Cancer Res. 2007;13:
5361–5367.
25. Jeronimo C, Bastian PJ, Bjartell A, et al. Epigenetics in prostate cancer:
biologic and clinical relevance. Eur Urol. 2011;60:753–766.
26. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic
markers in progressive, castration-resistant prostate cancer: a
reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10: 233–239.
27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation
criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J
Cancer. 2009;45:228–247.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
supporting information tab for this article.
How to cite this article: Hendriks RJ, Dijkstra S, Smit FP,
et al. Epigenetic markers in circulating cell-free DNA as
prognostic markers for survival of castration-resistant
prostate cancer patients. The Prostate. 2018;78:336–342.
https://doi.org/10.1002/pros.23477
342 | HENDRIKS ET AL.
